<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00735241</url>
  </required_header>
  <id_info>
    <org_study_id>STX0207</org_study_id>
    <nct_id>NCT00735241</nct_id>
  </id_info>
  <brief_title>FOLFOX6 Plus Sir-Spheres Microspheres Plus Avastin in Patients With Nonresectable Liver Metastases From Colorectal Carcinoma</brief_title>
  <acronym>FAST</acronym>
  <official_title>Pilot Study of FOLFOX6 Plus Sir-SpheresÂ® Microspheres (Chemo-radiotherapy) in Combination With Bevacizumab (Avastin) as a First Line Treatment in Patients With Nonresectable Liver Metastases From Primary Colorectal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sirtex Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sirtex Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study will evaluate the safety and effectiveness of chemo-radiotherapy comprising
      a regimen of FOLFOX6 chemotherapy plus SIR-Spheres yttrium-90 microspheres
      (chemo-radiotherapy, also known as &quot;chemo-SIRT&quot;), in combination with the biologic therapy
      Bevacizumab (Avastin), for the first-line treatment of patients with liver metastases from
      colorectal carcinoma in whom surgical resection is not feasible.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Withdrawn by the study sponsor.
  </why_stopped>
  <start_date>July 2008</start_date>
  <completion_date type="Anticipated">March 2009</completion_date>
  <primary_completion_date type="Anticipated">March 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity and safety</measure>
    <time_frame>from study entry until 28 days after last cycle of chemotherapy</time_frame>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Colorectal Carcinoma</condition>
  <condition>Liver Metastases</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SIR-Spheres microspheres</intervention_name>
    <description>SIR-Spheres yttrium-90 microspheres</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX6 cycles 1-3</intervention_name>
    <description>Oxaliplatin 60 mg/m2, IV infusion, q 2 weeks Leucovorin 200 mg/m2, IV infusion, q 2 weeks 5-Fluorouracil 400 mg/m2, IV bolus, q 2 weeks 5-Fluorouracil 2.4 g/m2, IV infusion, q 2 weeks</description>
    <other_name>Eloxatin</other_name>
    <other_name>Folinic acid</other_name>
    <other_name>5-FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX6 cycles 4 onwards</intervention_name>
    <description>Oxaliplatin 85 mg/m2 given, IV infusion, q 2 weeks Leucovorin 200 mg/m2 given, IV infusion, q 2 weeks 5-Fluorouracil 400 mg/m2, IV bolus, q 2 weeks 5-Fluorouracil 2.4 g/m2, IV infusion, q 2 weeks</description>
    <other_name>Eloxatin</other_name>
    <other_name>Folinic acid</other_name>
    <other_name>5-FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab cycles 3 onwards</intervention_name>
    <description>Bevacizumab 10 mg/m2, IV infusion, q 2 weeks commencing with the third cycle of chemotherapy</description>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed adenocarcinoma of the colon or rectum.

          -  Unequivocal and measurable CT evidence of liver metastases which are not treatable by
             surgical resection or local ablation with curative intent.

          -  ECOG performance status 0 - 1.

          -  Adequate hematological, renal and hepatic function.

        Exclusion Criteria:

          -  Evidence of ascites, cirrhosis, portal hypertension, main portal vein tumor
             involvement or thrombosis as determined by clinical or radiologic assessment.

          -  Any extra-hepatic metastases other than metastases in the lungs and/or bones and/or
             abdominal or hilar lymph nodes. Central nervous system (CNS) metastases are not
             allowed.

          -  Previous radiotherapy delivered to the upper abdomen.

          -  Peripheral neuropathy &gt; grade 1 (NCI-CTCv3).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis Carter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rocky Mountain Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charlie Nutting, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skye Ridge Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sacred Heart Medical Center</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2008</study_first_submitted>
  <study_first_submitted_qc>August 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 14, 2008</study_first_posted>
  <last_update_submitted>May 21, 2015</last_update_submitted>
  <last_update_submitted_qc>May 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2015</last_update_posted>
  <responsible_party>
    <name_title>David Cade, MD, Medical Director</name_title>
    <organization>Sirtex Technology Pty Ltd</organization>
  </responsible_party>
  <keyword>colon cancer</keyword>
  <keyword>colorectal cancer</keyword>
  <keyword>liver metastases</keyword>
  <keyword>SIR-Spheres Microspheres</keyword>
  <keyword>yttrium-90</keyword>
  <keyword>FOLFOX</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>chemo-radiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

